Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study

Mild cognitive impairment (MCI) often represents an early form of Alzheimer disease (AD). In both MCI and AD, characteristic cholinergic changes may occur. Functional magnetic resonance imaging (fMRI) may help to examine neurochemical changes in early disease by studying signal reactivity to pharmacological challenge. In this study, MCI patients [n=28; mean age 73.6+/-7.5; mini mental state examination (MMSE) 27.0+/-1.2] were scanned during task performance in a randomized trial under three different medication regimes: at baseline [BL; no galantamine (GAL)], after a single oral dose of GAL (SD), and after prolonged exposure (steady state: SS). Memory tasks included an episodic face-encoding task and a parametric n-letter back working memory (WM) task. Alterations in brain activation patterns before and after treatment were analyzed for both tasks using multilevel statistical analysis. Significant increases in brain activation from BL were observed after prolonged exposure only. For face encoding (n=28), these involved left prefrontal areas, the anterior cingulate gyrus, left occipital areas, and left posterior hippocampus. For working memory (n=28), increased activation was found in right precuneus and right middle frontal gyrus, coinciding with increased accuracy scores after GAL treatment. In conclusion, cholinergic challenge produces alterations in brain activation patterns in elderly MCI patients that can be detected with fMRI. This should encourage further functional imaging studies to examine the status of neurotransmitter systems in disease.

[1]  S J Heishman,et al.  Effect of nicotine on brain activation during performance of a working memory task , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  F Barkhof,et al.  Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer’s disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[3]  Stephen M. Smith,et al.  Temporal Autocorrelation in Univariate Linear Modeling of FMRI Data , 2001, NeuroImage.

[4]  M. Witter,et al.  Functional MR imaging in Alzheimer's disease during memory encoding. , 2000, AJNR. American journal of neuroradiology.

[5]  P. Doraiswamy,et al.  Brain Magnetic Resonance Spectroscopy , 2000 .

[6]  Stephen M. Smith,et al.  Improved Optimization for the Robust and Accurate Linear Registration and Motion Correction of Brain Images , 2002, NeuroImage.

[7]  Yu-Shin Ding,et al.  Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer’s dementia , 2001, Biological Psychiatry.

[8]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[9]  J. Haxby,et al.  Cholinergic enhancement and increased selectivity of perceptual processing during working memory. , 2000, Science.

[10]  Jonathan D. Cohen,et al.  Improved Assessment of Significant Activation in Functional Magnetic Resonance Imaging (fMRI): Use of a Cluster‐Size Threshold , 1995, Magnetic resonance in medicine.

[11]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[12]  M D'Esposito,et al.  A Neural Network Reflecting Decisions about Human Faces , 2001, Neuron.

[13]  C. Jack,et al.  Comparison of memory fMRI response among normal, MCI, and Alzheimer’s patients , 2003, Neurology.

[14]  Stephen Smith,et al.  Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. , 2003, Brain : a journal of neurology.

[15]  Changiz Geula,et al.  Abnormalities of neural circuitry in Alzheimer's disease , 1998, Neurology.

[16]  Karl J. Friston,et al.  Assessing the significance of focal activations using their spatial extent , 1994, Human brain mapping.

[17]  M. Mesulam.  The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? , 2004, Learning & memory.

[18]  S. Wisniewski,et al.  Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment , 2002, Annals of neurology.

[19]  S. Rose.  'Smart Drugs': do they work? Are they ethical? Will they be legal? , 2002, Nature Reviews Neuroscience.

[20]  R. Bartus,et al.  On Neurodegenerative Diseases, Models, and Treatment Strategies: Lessons Learned and Lessons Forgotten a Generation Following the Cholinergic Hypothesis , 2000, Experimental Neurology.

[21]  Edward D Levin,et al.  Cognitive effects of nicotine , 2001, Biological Psychiatry.

[22]  M M Mesulam,et al.  The systems-level organization of cholinergic innervation in the human cerebral cortex and its alterations in Alzheimer's disease. , 1996, Progress in brain research.

[23]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[24]  Stephen M. Smith,et al.  A global optimisation method for robust affine registration of brain images , 2001, Medical Image Anal..

[25]  Mark W. Woolrich,et al.  Multilevel linear modelling for FMRI group analysis using Bayesian inference , 2004, NeuroImage.

[26]  D. Rubin,et al.  Activation in mesolimbic and visuospatial neural circuits elicited by smoking cues: evidence from functional magnetic resonance imaging. , 2002, The American journal of psychiatry.

[27]  M. Dam,et al.  A short review of cognitive and functional neuroimaging studies of cholinergic drugs: implications for therapeutic potentials , 2002, Journal of Neural Transmission.

[28]  Nathan Herrmann,et al.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[29]  B R Rosen,et al.  Encoding novel face‐name associations: A functional MRI study , 2001, Human brain mapping.

[30]  M. Torrens.  Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268 , 1990 .

[31]  E. Levin,et al.  Nicotinic acetylcholine involvement in cognitive function in animals , 1998, Psychopharmacology.

[32]  P. Clarke,et al.  Nicotinic Receptors and Cholinergic Neurotransmission in the Central Nervous System , 1995, Annals of the New York Academy of Sciences.

[33]  J. Cummings,et al.  Neuropsychiatric symptoms in the dementias , 2002, Current opinion in neurology.

[34]  Alan C. Evans,et al.  A Three-Dimensional Statistical Analysis for CBF Activation Studies in Human Brain , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  M. Mesulam,et al.  Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. , 1998, Brain : a journal of neurology.

[36]  N. Osselaer,et al.  The metabolism and excretion of galantamine in rats, dogs, and humans. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[37]  D. Schacter,et al.  Medial temporal lobe activations in fMRI and PET studies of episodic encoding and retrieval , 1999, Hippocampus.

[38]  J. O'Brien,et al.  Use of functional imaging in parkinsonism and dementia , 2003, Movement disorders : official journal of the Movement Disorder Society.

[39]  K. Sumikawa,et al.  Acute and chronic nicotine exposure differentially facilitate the induction of LTP , 1999, Brain Research.

[40]  Qinying Zhao,et al.  Pharmacokinetics and Safety of Galantamine in Subjects with Hepatic Impairment and Healthy Volunteers , 2002, Journal of clinical pharmacology.

[41]  Veena Kumari,et al.  Cognitive effects of nicotine in humans: an fMRI study , 2003, NeuroImage.

[42]  M. Raskind.  Update on Alzheimer Drugs (Galantamine) , 2003, The neurologist.

[43]  E. Stein,et al.  Cognitive Mechanisms of Nicotine on Visual Attention , 2002, Neuron.

[44]  Stephen M Smith,et al.  Fast robust automated brain extraction , 2002, Human brain mapping.

[45]  H. Braak,et al.  Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer? , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[46]  Trey Sunderland,et al.  Combined Nicotinic and Muscarinic Blockade in Elderly Normal Volunteers: Cognitive, Behavioral, and Physiologic Responses , 1998, Neuropsychopharmacology.

[47]  Douglas Greve,et al.  Functional MRI detection of pharmacologically induced memory impairment , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[48]  G. Small,et al.  Specificity of brain activation patterns in people at genetic risk for Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[49]  Kristine Yaffe,et al.  Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. , 2003, JAMA.

[50]  Paolo Vitali,et al.  Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[51]  R. Mayeux,et al.  Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease , 1999, Annals of neurology.

[52]  M. D’Esposito,et al.  Alterations in the BOLD fMRI signal with ageing and disease: a challenge for neuroimaging , 2003, Nature Reviews Neuroscience.

[53]  Edward E. Smith,et al.  A Parametric Study of Prefrontal Cortex Involvement in Human Working Memory , 1996, NeuroImage.